Senores Pharmaceuticals Reports Q4FY26 Results: PAT Jumps 104% YoY

Indian equity benchmark indices ended higher on Thursday, with the benchmark Nifty 50 index rising 1.18 per cent to close at 23,689.60. Despite the positive broader market sentiment, shares of Senores Pharmaceuticals traded lower on Thursday after the company announced its Q4FY26 and FY26 financial results. On Thursday, Senores Pharmaceuticals share price declined 1.96 per cent to close at Rs 954.65.

Senores Pharmaceuticals Q4FY26 Results

Senores Pharmaceuticals reported consolidated total income of Rs 190 crore in Q4FY26 as against Rs 114 crore reported in Q4FY25, registering a growth of around 66 per cent YoY.

Consolidated EBITDA stood at Rs 62 crore during the quarter compared to the corresponding quarter previous year, reflecting a growth of around 219 per cent YoY. Consolidated PAT came in at Rs 37 crore in Q4FY26, registering a growth of around 104 per cent YoY.

Regulated Markets revenue stood at Rs 117.8 crore in Q4FY26 compared to Rs 43.8 crore reported in Q4FY25, reflecting a growth of around 169 per cent YoY. Emerging Markets revenue rose to Rs 49.5 crore, while Branded Generics revenue increased to Rs 9.4 crore during the quarter.

Senores Pharmaceuticals FY26 Performance

For the financial year ended March 31, 2026, Senores Pharmaceuticals reported consolidated total income of Rs 664 crore as against Rs 402 crore reported in FY25, registering a growth of around 65 per cent YoY.

The company reported consolidated EBITDA of Rs 200 crore in FY26, reflecting a growth of around 114 per cent YoY. Consolidated PAT stood at Rs 122 crore during FY26 compared to the previous financial year, registering a growth of around 108 per cent YoY.

Key Business Developments

During FY26, Senores Pharmaceuticals expanded its regulated markets portfolio with 51 approved ANDAs covering 151 strengths. The company also has more than 30 approved ANDAs yet to be commercialised and 27 additional ANDAs under development involving over 65 strengths.

The company completed Phase 1 acquisition of a 75 per cent stake in Apnar Pharmaceuticals, with the remaining 25 per cent stake expected to be acquired by Q2FY27. Senores also acquired a 51 per cent membership interest in Zoraya Pharmaceuticals to strengthen its U.S. commercialization and distribution platform.

In April 2026, the company entered into a 70 per cent joint venture named Amerisyn in the U.S. federal pharmaceutical procurement market, including veterans affairs and military supply programs.

Management Commentary

Commenting on the FY26 performance, Swapnil Shah, Managing Director of Senores Pharmaceuticals, said the company delivered robust growth across segments driven by operational discipline, execution and momentum in key growth areas despite an uncertain operating environment.

He stated that the approved ANDA portfolio more than doubled from 26 ANDAs in March 2025 to 51 ANDAs in March 2026, while the Apnar Pharmaceuticals acquisition is expected to improve scalability, operating leverage and CDMO opportunities over the next 12–18 months.

About Senores Pharmaceuticals

Senores Pharmaceuticals Limited is a global research-driven pharmaceutical company engaged in developing and manufacturing pharmaceutical products for regulated and emerging markets including the U.S., Canada and other international markets. The company operates formulation and API manufacturing facilities in India and the United States.

Comments: Share your views on Senores Pharmaceuticals’ Q4FY26 performance in the comments below.

Disclaimer: This article is for informational purposes only and not investment advice.